Abstract
Purpose: :
To report the effect of the intravitreal bevacizumab treatment on the macular edema with serous macular detachment (SMD) in central retinal vein occlusion (CRVO).
Methods: :
Retrospective, interventional, noncomparative case series. Thirty-seven consecutive patients (37 eyes) with SMD underwent intravitreal bevacizumab treatment were analysed in the study. Complete ophthalmological examination included best corrected visual acuity (BCVA), fundus photography, fluorescein angiography and optical coherence tomography (OCT). SMD was diagnosed on OCT examination.
Results: :
The mean patient age was 67.6 years (range, 20 to 88 years) with a mean follow-up time of 83 weeks (range 4 to 208 weeks). The mean number of injections was 3.9 ± 2.6. CRVO was non-ischemic in 25 (67.6%), and ischemic in 12 eyes (32.4%). Ten eyes had previous treatment that did not result in the resolution of the serous macular detachment. At the end of follow-up time, mean total retinal thickness had been reduced from 775µm to 556µm (p=0.003). Mean SMD had been reduced from 497µm to 225µm (p=0.0001). At the final visit 17 of the 37 eyes (46%) had complete resolution of the SMD. The mean logMAR BCVA improved from 1.05 to 0.93l (p = 0.17). No systemic or ocular complications were noted.
Conclusions: :
Our retrospective, noncomparative study shows that bevacizumab injection is effective for the decrease of the macular edema in eyes with SMD secondary to CRVO. However the improvement in vision did not reach a statistically significant level, possible due to the small number and heterogenous composition of the study collective. Further studies are warrented to clarify the predictive factors on the prognosis in eyes with SMD in CRVO.
Keywords: vascular endothelial growth factor • vascular occlusion/vascular occlusive disease • macula/fovea